What is new in the treatment of advanced melanoma? State of the art

Wspolczesna Onkologia

Volumn 16, Issue 5, 2012, Pages 363-370

  Mackiewicz, Jacek ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Anti CTLA4; BRAF inhibitor; Cancer vaccines; Immunotherapy; Melanoma

Indexed keywords

CANCER VACCINE; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; TRAMETINIB; VEMURAFENIB;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW;

EID: 84870162926     PISSN: 14282526     EISSN: None     Source Type: Journal    
DOI: 10.5114/wo.2012.31763     Document Type: Review

References (72)

1. Mackiewicz J, Kwinta L. New targeted therapies in the treatment of patients with metastatic melanoma. Contemp Oncol 2010; 14: 15-22.
2. National Cancer Registry http://www.onkologia.org.pl/pl/p/11.
3. Maio M, Mackiewicz A, Testori A, et al.; Thymosin Melanoma Investigation Group. Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma. J Clin Oncol 2010; 28: 1780-7.
4. Mackiewicz J, Mackiewicz A. Immunotargeting of melanoma, current management of malignant melanoma. Ming Y Cao (ed.). InTech 2011. Available from: http://www.intechopen.com/articles/show/title/immunotargeting-of-melanoma.
5. http://www.clinicaltrials.gov/ct2/show/NCT00636168?term= ipilimumab+adjuvant+melanoma&rank=1A.
6. http://www.clinicaltrials.gov/ct2/show/NCT00796445?term= MAGE+DERMA+melanoma&rank=2.
7. Hodis E, Watson IR, Kryukov GV, et al. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
8. Postow MA, Carvajal RD. Therapeutic implications of KIT in me - lanoma. Cancer J 2012; 18: 137-41.
9. Davies H, Bignelli GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54. (Pubitemid 34716871)
10. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alteration in melanoma. N Engl J Med 2005; 353: 2135-47. (Pubitemid 41653105)
11. Bauer J, Büttner P, Murali R, Okamoto I, Kolaitis NA, Landi MT, Scolyer RA, Bastian BC. BRAF mutations in cutaneus melanoma are independently associated with age, anatomic site of the primary tumor, ant the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 2011; 24: 345-351.
12. Romano E, Schwartz GK, Chapman PB, Wolchock JD, Carvajal RD. Treatment implications of the emerging molecular classification system for melanoma. Lancet Oncol 2011; 12: 913-22.
13. Arkenau HT, Kefford R, Long GV. Targeting BRAF for patients with melanoma. Br J Cancer 2011; 104: 392-8.
14. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366: 707-14.
15. Chapman PB, Hauschild A, Robert C, et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
16. Chapman PB, Hauschild A, Robert C et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAFV600E-mutated melanoma. J Clin Oncol 2012; 30 (suppl): abstr. 8502.
17. Larkin JMG, Queirolo P, Aranc AM et al. An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma. J Clin Oncol 2012; 30 (suppl): abstr. 8517.
18. V600E-mutated melanoma. J Clin Oncol 2012; 30 (suppl): abstr. LBA8500∧.
19. Kirkwood JM, Long GV, Trefzer U, et al. BREAK-MB: A phase II study assessing overall intracranial response rate (OIRR) to dabrafenib (GSK2118436) in patients (pts) with BRAF V600E/k mutation-positive melanoma with brain metastases (mets). J Clin Oncol 2012; 30 (suppl): abstr. 8501.
20. Kudchadkar R, Paraiso KH, Smalley K. Targeting mutant BRAF in Melanoma. Current status and future development of combination therapy strategies. Cancer J 2012; 18: 124-31.
21. 600E/K mutant advanced or metastatic melanoma (MM). J Clin Oncol 2012; 30 (suppl): abstr. LBA8509.
22. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phosphor-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010; 102: 1724-30.
23. Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968-72.
24. Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to inhibition in melanoma by genomic profiling. J Clin Oncol 2011; 29: 3085-96.
25. Poulikakos PI, Persuad Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerazation of aberrantly spliced BRAF (V600E). Nature 2011; 480: 387-90.
26. Weber JS, Flaherty KT, Jeffrey R. InfanteUpdated safety and efficacy results from a phase I/II study of the oral BRAF inhibitor dabrafenib (GSK2118436) combined with the oral MEK 1/2 inhibitor trametinib (GSK1120212) in patients with BRAF-naive metastatic melanoma. J Clin Oncol 2012; 30 (suppl): abstr. 8510.
27. Kalinsky K, Lee SJ, Lawrence DP, et al. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). J Clin Oncol 2012; 30 (suppl): abstr. 8522.
28. http://www.clinicaltrials.gov/ct2/results?term=NCT01028222.
29. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
30. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-26.
31. Maio M, Lebbé C, Sileni VCh, et al. Long-term survival in advanced melanoma patients treated with ipilimumab at 10 mg/kg: ongoing analyses from completed phase II Trials. ESMO Congress 2009; poster 116.
32. Maio M, Lebbé C, Neyns B, et al. Three-year survival rates for patients with advanced melanoma who received ipilimumab at 10 mg/kg in Phase II Trials. Congress - Perspectives in Melanoma XIV, Amsterdam 2010; poster P-0020.
33. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-64.
34. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: amulticenter single-arm phase II study. Ann Oncol 2010; 21: 1712-17.
35. O'Day SJ, Maio M, Chiarion-Sileni V, et al. A randomized,double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009; 15: 5591-8.
36. Kähler KC, Hauschild A. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma. J Dtsch Dermatol Ges 2011; 9: 277-86.
37. Lebbé C. Perspectives in Melanoma XII 2008; abstr. O-015.
38. Hersey P, Smalley KS, Weeraratna A, et al. Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell Melanoma Res 2011; 24: 1: e1-15.
39. Weber J. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010). Oncologist 2008; 13 Suppl 4: 16-25.
40. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13 (22 Pt 1): 6681-8. (Pubitemid 350206804)
41. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-30.
42. Hamid O, Urba WJ, YellinM. et al. Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. J Clin Oncol 2007; 25 (Suppl. 25): abstr. 8525.
43. Wolchok J. Cancer Immunology & Immunotherapy. XVIth Meeting of the Cancer Research Institute 2008; abstr. S25.
44. O Hamid, WJ Hwu, JM Richards et al. Ipilimumab (Ipi) expanded access program (EAP) for patients (pts) with stage III/IV melanoma: 10 mg/kg cohort interim results. J Clin Oncol 2012; 30 (suppl): abstr. 8508.
45. http://www.clinicaltrials.gov/ct2/show/NCT01515189?term= ipilimumab+melanoma+10+mg+3+mg&rank=1.
46. Harding JJ, Lacouture ME, Pulitzer M, et al. Hypersensitivity skin reactions in melanoma patients treated with vemurafenib after ipilimumab therapy. J Clin Oncol 2012; 30 (suppl): abstr. 8515.
47. Ribas A, Hodi FS, Kurland JF, et al. CA184-161: A phase I/II trial of vemurafenib and ipilimumab in patients with BRAF V600 mutation-positive metastatic melanoma. J Clin Oncol 2012; 30 (suppl): abstr. TPS8603.
48. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-65.
49. Maio M, Testori A, Ascierto PA, et al. The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases. J Clin Oncol 2012; 30 (suppl): abstr. 8529.
50. Kirkwod JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. J Clin Oncol 2008; (suppl. 26): abstr. 9023.
51. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008; (suppl. 26): abstr. LBA9011.
52. Tarhini AA, Moschos SS, Schlesselman JJ, et al. Phase II trial combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or IV melanoma. J Clin Oncol 2008; (suppl. 26): abstr. 9009.
53. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses. Immunity 2007; 27: 111-22. (Pubitemid 47089023)
54. Hodi FS, Sznol M, McDermott DF, et al. Clinical activity and safety of anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced melanoma (MEL). J Clin Oncol 2012; 30 (suppl): abstr. 8507.
55. Kudchadkar RR, Gallenstein D, Martinez AJ, et al. Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma. J Clin Oncol 2012; 30 (suppl): abstr. 8582.
56. Sznol M, Hodi FS, Margolin K. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 2008; (suppl): abstr. 3007.
57. http://www.clinicaltrials.gov/ct2/show/NCT00612664?term= BMS-663513&rank=6.
58. Vonderheide RH, Flaherty K, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2006; 25: 876-83. (Pubitemid 350002889)
59. http://www.clinicaltrials.gov/ct2/show/NCT00607048?term= CP-870%2C893&rank=3.
60. Morton DL, Mozzillo N, Thompson JF, et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic or regional or distant sites. J Clin Oncol 2007; (suppl): abstr. 8508.
61. Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8: 3696-6701.
62. Mackiewicz J, Mackiewicz A. Gene-modified cellular vaccines: technologic aspects and clinical problems. Transplant Proc 2010; 42: 3287-92.
63. Mackiewicz A, Mackiewicz J, Wysocki PJ, et al. Long-term survival of high-risk melanoma patients immunized with a hyper-IL-6- modified allogeneic whole-cell vaccine after complete resection. Expert Opin Investig Drugs 2012; 21: 773-83.
64. Eggermont AMM, Suciu S, Samtinam M, et al. Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma. Final results of EORTC 18891, a randomized phase 3 trial. Lancet 2008; 372: 117-26. (Pubitemid 351952257)
65. Eigentler TK, Radny P, Hauschild A, et al. Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008; 18: 363-8.
66. Bystryn JC, Zeleniuch-Jacquotte A, Oratz R, et al. Double-blind trial of polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2011: 1882-7.
67. Pennacchioli E, Gandini S, Verrecchia F, et al. Surgery in stage IV melanoma patients: Results from a single institution. J Clin Oncol 2012; 30 (suppl): abstr. e19035.
68. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-52. (Pubitemid 28155090)
69. Hart DN. Dendritic cells: unique leukocyte populatons which control the primary immune response. Blood 1997; 90: 3245-87. (Pubitemid 27473395)
70. Schadendorf D, Ugurel S, Schuler-Thurner B, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol 2006; 17: 563-70.
71. Engel-Noerregaard L, Hansen TH, Andersen MH, Straten PT, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother 2009; 58: 1-14.
72. NN Petenko, IN Mikhaylova, GZ Chkadua, AY Baryshnikov, LV Demidov et al. Adjuvant dendritic cell (DC)-based vaccine therapy of melanoma patients. J Clin Oncol 2012; 30 (suppl): abstr. 2524.